Opinion|Videos|April 1, 2024
Paradigm Shift In Parkinson’s Disease Diagnosis
Author(s)Stuart H. Isaacson, MD, FAAN, Rajesh Pahwa, MD
The neurology experts discuss the importance of early and accurate diagnosis of Parkinson’s disease, the role of alpha-synuclein in the diagnosis of synucleinopathies and approaches to implementing screening protocols in clinical practice.
Advertisement
Episodes in this series
0:50 Diagnosis of Parkinson’s disease
3:20 Preclinical start of Parkinson’s disease
5:00 Alpha-synuclein in Parkinson’s disease
6:50 Biomarkers in Parkinson’s disease
12:00 Syn-One test for Parkinson’s disease
21:15 Advanced diagnostics in Parkinson’s disease
Advertisement
Related to this article
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
Michela Leocadi, PhD, research fellow at UCL Queen Square Institute of Neurology, discussed new longitudinal data showing early functional connectivity changes in HD gene carriers years before clinical motor diagnosis.
In a phase 4 randomized controlled trial, opicapone failed to demonstrate statistical superiority over placebo for reducing fluctuation-related pain in patients living with Parkinson disease.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.
A newly launched global phase 3 trial will compare once-daily trientine to D-penicillamine as a first-line treatment for patients with Wilson disease, a rare genetic disorder.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
2
FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis
3
Episode 175: Advancing the Ways of Treating Cluster Headache
4
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
5